Recursion Pharmaceuticals Inc Class A RXRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Recursion to Participate in Upcoming Investor Conferences
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Recursion Appoints Fred Hassan as Chair of the Board
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
Trading Information
- Previous Close Price
- $3.33
- Day Range
- $3.16–3.34
- 52-Week Range
- $2.77–5.24
- Bid/Ask
- $3.16 / $3.18
- Shares Outstanding
- 623.37M
- Market Cap
- $1.99B
- Volume/Avg
- 17M / 23M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 600
- Website
- https://www.recursion.com
Valuation
Metric | RXRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.97 |
Price/Sales | 25.27 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RXRX |
|---|---|
Quick Ratio | 4.75 |
Current Ratio | 5.01 |
Interest Coverage | −548.84 |
Quick Ratio
RXRX
Profitability
Metric | RXRX |
|---|---|
Return on Assets (Normalized) | −29.18% |
Return on Equity (Normalized) | −38.62% |
Return on Invested Capital (Normalized) | −37.91% |
Return on Assets
RXRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|qn>W#^y | LOCK|!H%@^ | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|v%@gS$ | LOCK|#S^? | $99B | |||
| Moderna Inc MRNA | LOCK|Fd>!k? | LOCK|GQW | $90B | |||
| argenx SE ADR ARGX | LOCK|c&m>$w | LOCK|!L | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|t>##!C | LOCK|y! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|xYh#kyMW | LOCK|#!TB% | $31B | |||
| Incyte Corp INCY | LOCK|PJrV^xG | LOCK|V>w | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|K&HQ%B | LOCK|r%!HY | $22B | |||
| BioNTech SE ADR BNTX | LOCK|mzzm>X | LOCK|<H | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!FdMCr? | LOCK|&q | $16B |
United States